Dapansutrile

Phase 3Small molecule

OOlatec Therapeutics LLC

Dapansutrile is one of 62 small molecule programs targeting Complication. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

CardiovascularNot yet recruiting

AcuteRecruiting

MelanomaPhase 2

Active, not recruiting

CardiovascularPhase 1

Not yet recruiting

AcutePhase 3

Recruiting

Competition

Competitive Landscape

177 competitors in Melanoma

#DrugCompanyPhaseTrials

Opdivo

Keytruda

93 3

Cotellic

Roche

Phase 3

21 4

Mektovi

Pfizer

Phase 3

12 5

Tecentriq

Roche

Phase 3

11 6

Libtayo

Regeneron

Phase 3

5 7

Fabhalta

Regeneron

Phase 3

2 8

Talimogene Laherparepvec

Amgen

Phase 3

14 9

Cyklokapron

JJ Molner

Phase 3

1 10

Rhuph20

Bristol-Myers Squibb

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Recruiting

Acute

NCT05658575

Q2 2027

Phase 1/2Active, not recruiting

Melanoma

NCT04971499

Q2 2028

Phase 2Recruiting

Parkinson Disease

NCT07157735

Q3 2028

Phase 2Recruiting

Complication

NCT06047262

Clinical

Trials by Indication[1]

Pilot Study1 trial

Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome

Terminated·OOlatec Therapeutics LLC·Phase 2·NCT03595371·2 enrolled

Melanoma1 trial

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

Active, not recruiting·—·Phase 1/2·NCT04971499·26 enrolled

Cardiovascular1 trial

Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI

Not yet recruiting·UUniversity of Virginia·Phase 1·NCT05880355·60 enrolled

COVID-191 trial

Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

Terminated·OOlatec Therapeutics LLC·Phase 2·NCT04540120·49 enrolled

Heart Failure1 trial

Study of Dapansutrile Capsules in Heart Failure

Completed·OOlatec Therapeutics LLC·Phase 1·NCT03534297·30 enrolled

3 more indications

Complication1 trial

Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

Recruiting·MMarc Donath·Phase 2·NCT06047262·300 enrolled

Acute1 trial

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Recruiting·OOlatec Therapeutics LLC·Phase 2/3·NCT05658575·300 enrolled

Parkinson disease1 trial

Anti-inflammatory Intervention With Dapansutrile (OLT1177®) for Parkinson's Disease Modification (DAPA-PD): A Randomised Double-Blind, Placebo-Controlled Phase II Trial

Recruiting·CCambridge University Hospitals NHS Foundation Trust·Phase 2·NCT07157735·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Dapansutrile. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dapansutrile compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dapansutrile. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Olatec Therapeutics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOlatec Therapeutics LLC

Dapansutrile

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q2 2028

Q3 2028

Trials by Indication[1]

Pilot Study1 trial

Melanoma1 trial

Cardiovascular1 trial

COVID-191 trial

Heart Failure1 trial

Complication1 trial

Acute1 trial

Parkinson disease1 trial

References

Drug Info

Quick Facts

Related News